117 related articles for article (PubMed ID: 21417612)
1. Niosomal encapsulation of the antitubercular drug, pyrazinamide.
El-Ridy MS; Abdelbary A; Nasr EA; Khalil RM; Mostafa DM; El-Batal AI; Abd El-Alim SH
Drug Dev Ind Pharm; 2011 Sep; 37(9):1110-8. PubMed ID: 21417612
[TBL] [Abstract][Full Text] [Related]
2. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.
El-Ridy MS; Mostafa DM; Shehab A; Nasr EA; Abd El-Alim S
Int J Pharm; 2007 Feb; 330(1-2):82-8. PubMed ID: 17049192
[TBL] [Abstract][Full Text] [Related]
3. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin.
El-Ridy MS; Abdelbary A; Essam T; El-Salam RM; Kassem AA
Drug Dev Ind Pharm; 2011 Dec; 37(12):1491-508. PubMed ID: 21707323
[TBL] [Abstract][Full Text] [Related]
4. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
5. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
Mokhtar M; Sammour OA; Hammad MA; Megrab NA
Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
[TBL] [Abstract][Full Text] [Related]
6. Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.
Mehta SK; Jindal N
Colloids Surf B Biointerfaces; 2013 Jan; 101():434-41. PubMed ID: 23010052
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of niosomes containing ribavirin for liver targeting.
Hashim F; El-Ridy M; Nasr M; Abdallah Y
Drug Deliv; 2010 Jul; 17(5):282-7. PubMed ID: 20350052
[TBL] [Abstract][Full Text] [Related]
8. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation.
Aggarwal D; Garg A; Kaur IP
J Pharm Pharmacol; 2004 Dec; 56(12):1509-17. PubMed ID: 15563757
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
10. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
[TBL] [Abstract][Full Text] [Related]
11. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
12. [A study of the bacteriophage-based assay for the detection of pyrazinamide resistance in Mycobacterium tuberculosis].
Ao JP; Chen JW; Hu ZY; Li JN; Wang J; Wang Q; Cui ZL; Zhang WH; Wong XH
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):625-8. PubMed ID: 17129472
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Guinedi AS; Mortada ND; Mansour S; Hathout RM
Int J Pharm; 2005 Dec; 306(1-2):71-82. PubMed ID: 16263229
[TBL] [Abstract][Full Text] [Related]
14. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of niosomes containing rifampicin for lung targeting.
Jain CP; Vyas SP
J Microencapsul; 1995; 12(4):401-7. PubMed ID: 8583314
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary delivery of pyrazinamide-loaded large porous particles.
Pham DD; Grégoire N; Couet W; Gueutin C; Fattal E; Tsapis N
Eur J Pharm Biopharm; 2015 Aug; 94():241-50. PubMed ID: 26036447
[TBL] [Abstract][Full Text] [Related]
18. Effect of formulation compositions on niosomal preparations.
Chaw CS; Kim KY
Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
[TBL] [Abstract][Full Text] [Related]
19. [Pyrazinamide monoresistant Mycobacterium tuberculosis in Manisa region, Turkey].
Ozkütük N; Ecemiş T; Sürücüoğlu S
Mikrobiyol Bul; 2008 Oct; 42(4):585-90. PubMed ID: 19149079
[TBL] [Abstract][Full Text] [Related]
20. [Status quo of pyrazinamide as an antituberculosis drug].
Kameda K
Kekkaku; 1995 Jul; 70(7):445-55. PubMed ID: 7564054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
